It's good to see everybody, and welcome back to TD Cowen's 46th Annual Healthcare Conference. It is my pleasure to be joined today by Recursion's CFO, Ben Taylor. We've got a lot of great stuff to ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Low Risk Penny Stocks to Buy Now. On February 27, Bank of America ...

Recursion Pharmaceuticals (NASDAQ:RXRX) used its latest earnings call to emphasize what management described as an inflection ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA talks.

Recursion Pharmaceuticals Inc RXRX shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp NVDA has fully exited its investment in the AI‑focused drug‑discovery ...

Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...

Shares of Recursion Pharmaceuticals RXRX are surging Wednesday following a robust earnings report released before the bell.

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...